Daratumumab Maintenance Therapy for Improving Survival in Patientes With Light Chain Amyloidosis, EMILIA Trial | oneAMYLOIDOSISvoice
×
recrutement

Daratumumab Maintenance Therapy for Improving Survival in Patientes With Light Chain Amyloidosis, EMILIA Trial

information clé

numéro d'identification de l'étude : NCT05898646

condition: Amylose AL

statut: Recrutement

objectif:

This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab for light chain (AL) amyloidosis. Maintenance therapy is treatment that is given to help keep cancer from coming back after it has disappeared following initial therapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Daratumumab is commonly prescribed as initial treatment for patients with AL amyloidosis. However, it is not known what role daratumumab may play in the maintenance therapy period of patients with AL amyloidosis. This phase II trial compares shorter duration maintenance to longer duration maintenance for improving survival in patients with AL amyloidosis.

intervention: Bone Marrow Aspiration, Daratumumab, Echocardiography, Questionnaire Administration, X-Ray Imaging, Biospecimen Collection

résultats: https://clinicaltrials.gov/ct2/show/results/NCT05898646

dernière mise à jour: 22 février 2024

détails de l'étude

date de début: 17 juillet 2023

achèvement estimée: 1 novembre 2024

dernière mise à jour: 17 janvier 2024

phase de développement : Phase 2

taille / inscription: 96

descriptif de l'étude : OBJECTIF PRINCIPAL:

I. To determine the event-free survival (EFS) after 3-6 versus 18 cycles of daratumumab maintenance following 6 cycles induction of daratumumab-cyclophosphamide-bortezomib-dexamethasone (CyBorD) in newly diagnosed AL amyloidosis.

OBJECTIFS SECONDAIRES :

I. To determine the rate of hematological response at end of maintenance in each arm.

II. To assess minimal residual disease rates by next generation multiparametric flow cytometry at study registration and at the end maintenance.

III. To determine organ response rate at 6, 12, 18, 24 and 36 months from registration in each arm (organ response will be assessed based on organ-related values at diagnosis).

IV. To determine time to next therapy (TTNT) after 3-6 versus 18 cycles daratumumab maintenance.

V. To determine time to organ response in those who did not achieve organ response at trial registration.

VI. To determine time to deep organ response based on revised organ response criteria for heart and kidneys.

VII. To determine time to organ progression, defined as the time between registration to date of organ progression per organ progression criteria.

VIII. To determine rate of pneumonia, sepsis and/or upper respiratory infections and any grade >= 3 infection in both arms within 3 years from registration.

IX. To determine overall survival after 3-6 versus 18 cycles daratumumab maintenance.

CORRELATIVE RESEARCH OBJECTIVE:

I. To assess overall health-related quality of life, as measured by Patiente Reported Outcomes Measurement Information System (PROMIS)-29 health questionnaire and selected items for the Patiente Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) questionnaire at registration, and at 3, 6, 12, 18 and 36 months from registration.

OUTLINE: Patientes are randomized to 1 of 2 arms.

ARM I: Patientes receive daratumumab subcutaneously (SC) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 6 cycles on study. Patientes also undergo x-ray imaging at screening and bone marrow biopsy and blood sample collection throughout the study. Patientes with cardiac involvement also undergo echocardiography throughout the trial.

ARM II: Patientes receive daratumumab SC on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 18 cycles on study. Patientes also undergo x-ray imaging at screening and bone marrow biopsy and blood sample collection throughout the study. Patientes with cardiac involvement also undergo echocardiography throughout the trial.

After completion of study treatment, patients are followed up every 6 months for up to 36 months from registration, and then up to 5 years from starting the study for survival status.

résultats principaux :

  • Event free survival
    The point estimate for the hazard ratio and corresponding one-sided 85% confidence interval will be generated with a stratified Cox regression (using the trial stratification factors) that has treatment arm as an exploratory variable.
  • From registration up to 36 months

résultats secondaires :

  • Hematological response
    At the end of maintenance treatment
  • Minimal residual disease (MRD) negativity rate
    Jusqu'à mois 36
  • Taux de réponse des organes
    At 6, 12, 18, 24, and 36 months from registration
  • Survie globale (OS)
    Time from registration to death from any cause, assessed up to 5 years

Critère d'intégration:

• Âges éligibles : 18 ans et plus
• Sexes admissibles : tous
Critère d'intégration:

Âge> = 18 ans
Histological confirmation of AL amyloidosis with adequate typing (mass spectrometry, immunohistochemistry, immunofluorescence, immunogold)

AL amyloidosis with organ disease requiring therapy

NOTE: Disease requiring therapy is referred to the time of diagnosis. There are no limitations in baseline measurable disease parameters

Patientes must have monoclonal protein studies (serum free light chain assay, serum immunofixation or serum MASS-FIX) obtained at time of diagnosis before induction therapy initiated and available for review to be enrolled.

NOTE: Patientes are allowed to participate in this study if urine electrophoresis immunofixation study was not done at time of diagnosis or cannot be obtained
Patientes must have completed 6 cycles of daratumumab (Dara)-CyBorD-based induction treatment =< 84 days prior to registration

Patientes must have achieved a hematological complete response (CR) (irrespective of organ response achievement) or hematological very good partial response (VGPR) (irrespective of organ response achievement) or hematological low-difference in involved and uninvolved free light chain (dFLC) partial response (PR) (irrespective of organ response achievement) or hematological PR with at least one organ response after receiving Dara-CyBorD-based induction.

NOTE: Patientes with baseline dFLC < 5 mg/dL, must have achieved hematological CR, or dFLC < 1 mg/dL or achieved organ response prior to randomization

Patientes in whom bortezomib and/or cyclophosphamide were omitted from induction due to toxicity concerns or adverse effects are allowed. Patientes must receive at least daratumumab and dexamethasone at induction to qualify for the study

NOTE: Dexamethasone use does not need to be carried to end of induction for eligibility consideration
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3
Hemoglobin >= 8.0 g/dL (obtained =< 28 days prior to registration)
Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 28 days prior to registration)
Platelet count >= 50,000/mm^3 (obtained =< 28 days prior to registration)

Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only.

NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Provide written informed consent

NOTE: Informed consent required =< 90 days prior registration
Capacité à remplir un ou plusieurs questionnaires par eux-mêmes ou avec de l'aide
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)

critère d'exclusion: Critères:

Any of the following because this study involves an agent that has possible genotoxic, mutagenic and teratogenic effects:

Personnes enceintes
Personnes infirmières
Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception
Received >1 cycle of daratumumab maintenance after end of induction therapy and prior to registration

Multiple myeloma at time of diagnosis as defined by any of the following:

Hypercalcemia: Serum calcium > 1 mg/dL higher than upper limit of normal or > 11 mg/dL
Renal insufficiency: Creatinine clearance < 40 mL per min or serum creatinine > 2 mg/dL attributed to high circulating light chains (i.e. cast nephropathy) or hypercalcemia
Anemia: Hemoglobin > 2 g/dL below lower limit of normal, or < 10 g/dL, attributed to high marrow myeloma infiltration
Bone lesions: >= 1 osteolytic lesion on skeletal x-ray, computed tomography (CT), or positron emission tomography (PET)-CT (bone imaging is not mandatory but based on clinical suspicion)
Clonal bone marrow plasma cells >= 60%
> 1 focal lesion on magnetic resonance imaging (MRI) (MRI is not mandatory but based on clinical suspicion)

If bone imaging (CT, MRI, PET-CT) was not done at time of diagnosis it is not needed to be performed at registration to rule out bone disease

>= 40% BMPCs irrespective of the above
The study will allow patients with involved: uninvolved serum-free light chain (sFLC) ratio >= 100 if this is the only criteria that defines amyloidosis if all the above criteria are not met
Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Note: Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR

Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy.

NOTE: Patientes known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial

Uncontrolled intercurrent illness including, but not limited to:

Ongoing or active infection
Angine de poitrine instable
Maladie psychiatrique / situations sociales qui limiteraient le respect des exigences de l'étude

parrainer: Mayo Clinic

contacts: Bureau de référence pour les essais cliniques, 855-776-0015, [email protected]

les enquêteurs: Eli Muchtar, M.D.,Mayo Clinic In Rochester

emplacements des centres d'essai : États-Unis

Pour améliorer votre expérience sur ce site, nous utilisons des cookies. Cela inclut les cookies essentiels au fonctionnement de base de notre site Web, les cookies à des fins d'analyse et les cookies nous permettant de personnaliser le contenu du site. En cliquant sur «Accepter» ou sur tout contenu de ce site, vous acceptez que des cookies puissent être placés. Vous pouvez ajuster les paramètres des cookies de votre navigateur en fonction de vos préférences.
Plus d'information

Les paramètres des cookies sur ce site est mis à "accepter les cookies" pour vous donner la meilleure expérience de navigation possible. Si vous continuez à utiliser ce site sans changer vos paramètres de cookies ou vous cliquez sur «Accepter» Consentir ci-dessous et que vous avez à présent.

Fermer

Pour améliorer votre expérience sur ce site, nous utilisons des cookies. Cela inclut les cookies essentiels au fonctionnement de base de notre site Web, les cookies à des fins d'analyse et les cookies nous permettant de personnaliser le contenu du site. En cliquant sur «Accepter» ou sur tout contenu de ce site, vous acceptez que des cookies puissent être placés. Vous pouvez ajuster les paramètres des cookies de votre navigateur en fonction de vos préférences.
Plus d'information

Les paramètres des cookies sur ce site est mis à "accepter les cookies" pour vous donner la meilleure expérience de navigation possible. Si vous continuez à utiliser ce site sans changer vos paramètres de cookies ou vous cliquez sur «Accepter» Consentir ci-dessous et que vous avez à présent.

Fermer